Levosimendan Tillomed (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances contractile force without raising intracellular calcium levels. In addition, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that reduces after‑load and improves overall cardiac efficiency.

The dosing regimen for Levosimendan Tillomed is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. A typical protocol may include a loading infusion followed by a continuous maintenance infusion, but exact rates and durations are set by the treating physician.

Safety data for Levosimendan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Levosimendan differs from traditional catecholamine inotropes like dobutamine by sensitising troponin C to calcium rather than increasing intracellular calcium. This mechanism can provide sustained contractility with less risk of tachyarrhythmias. Additionally, its vasodilatory effect reduces after‑load, whereas dobutamine primarily increases heart rate and contractility without significant vasodilation.

Levosimendan Tillomed must be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking. If the product must be transported, use validated cold‑chain packaging to maintain the required temperature range throughout delivery.

Levosimendan is given as an intravenous infusion. After reconstitution, a loading dose may be administered over a short period, followed by a continuous maintenance infusion. The infusion is performed under clinical monitoring to assess blood pressure, heart rate and cardiac rhythm throughout the treatment.

The most serious adverse events include severe hypotension, ventricular arrhythmias, myocardial ischaemia and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for rapid changes in blood pressure and cardiac rhythm, and immediate medical intervention should be available if these events occur.

Levosimendan is contraindicated in patients with severe hypotension, recent myocardial infarction, uncontrolled ventricular arrhythmias, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal or hepatic impairment, and it should be avoided in patients for whom vasodilation could worsen their clinical condition.